ced pexels 7089293

Cannabidiol Effects on Brain Excitability: Clinical Trial (57 characters – includes keyword “clinical” from primary search terms while maintaining accuracy to the trial’s negative finding on cortical excitability)

Clinical Takeaway

CBD does not directly reduce cortical excitability at doses tested (30-700 mg), suggesting its anti-seizure effects in approved clinical uses may depend on interactions with other medications like clobazam rather than independent brain activity suppression. This finding clarifies that CBD’s mechanism in seizure management differs from traditional anticonvulsants that directly alter neuronal firing patterns.

Cannabidiol Effects on Brain Excitability: Clinical Trial(57 characters - includes keyword

#11 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.

Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.

Study type: Journal Article, Randomized Controlled Trial  |  Topic area: Cannabidiol  |  CED Score: 11

Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0

Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30โ€‰mg CBD, 700โ€‰mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3โ€‰hours post-dose for 30โ€‰mg CBD, and at 3 and 5โ€‰hours post-dose for 700โ€‰mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.

 |   | 

View on PubMed ↗Full Text ↗DOI ↗


Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance